Learn how ESR1 mutations drive endocrine resistance and how FDA-approved oral SERDs improve outcomes, shaping smarter sequencing and future combos.
Oral Selective Estrogen Receptor Degraders in HR-Positive/HER2- Negative Metastatic Breast Cancer: Clinical Insights on Sequencing, Biomarkers, and Emerging Combinations
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
The OncFive: Top Oncology Articles for the Week of 8/9
4
Dr Viansone on De-Escalating Chemotherapy Type and Duration in HER2-Positive Breast Cancer
5